Autolus Therapeutics (AUTL) Hisse Özeti
Klinik aşamada bir biyofarmasötik şirketi olan Autolus Therapeutics plc, Birleşik Krallık'ta ve uluslararası alanda kanser ve otoimmün hastalıkların tedavisi için T hücre tedavileri geliştirmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 2/6 |
| Temettüler | 0/6 |
AUTL Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Autolus Therapeutics plc Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$1.70 |
| 52 Haftanın En Yüksek Seviyesi | US$2.70 |
| 52 Haftanın En Düşük Seviyesi | US$1.18 |
| Beta | 1.93 |
| 1 Aylık Değişim | 6.25% |
| 3 Aylık Değişim | 1.80% |
| 1 Yıllık Değişim | 10.39% |
| 3 Yıllık Değişim | -39.93% |
| 5 Yıllık Değişim | -74.36% |
| Halka arzdan bu yana değişim | -93.20% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • May 18
AUTL: Early Commercial Traction And Cost Actions Will Support A Brighter Outlook
Analysts have adjusted their fair value estimate for Autolus Therapeutics to $11.00 from $13.00, citing updated assumptions around revenue growth, profitability, and future P/E, along with recent shifts in Street price targets following the Q1 report and Aucatyzl launch trends in the U.S. and UK. Analyst Commentary Recent Street commentary reflects a mix of optimism and recalibration around Autolus Therapeutics, with bullish analysts pointing to early commercial trends for Aucatyzl as a key driver for their views on valuation and execution.
Anlatı Güncellemesi • May 03
AUTL: Rebased Profit Assumptions Set Stage For Future Upside Execution
Analysts have reduced their price targets on Autolus Therapeutics by $2 to $3, citing updated assumptions on discount rates, profit margins, and future P/E levels that temper prior expectations. Analyst Commentary Bullish Takeaways Bullish analysts see the updated discount rates and profit margin assumptions as a reset that can make future execution milestones more impactful for valuation, rather than relying on aggressive prior models.Anlatı Güncellemesi • Apr 18
AUTL: Higher Risk Assumptions Will Still Support Upside Potential
Analysts have modestly lifted their fair value estimate for Autolus Therapeutics from $8.79 to $8.81, tying the change to updated assumptions for discount rates, revenue growth, profit margins, and future P/E, along with recent price target revisions from the Street. Analyst Commentary Recent Street research has focused on recalibrating price targets for Autolus Therapeutics, which feeds directly into the modest change in fair value.Recent updates
Anlatı Güncellemesi • May 18
AUTL: Early Commercial Traction And Cost Actions Will Support A Brighter Outlook
Analysts have adjusted their fair value estimate for Autolus Therapeutics to $11.00 from $13.00, citing updated assumptions around revenue growth, profitability, and future P/E, along with recent shifts in Street price targets following the Q1 report and Aucatyzl launch trends in the U.S. and UK. Analyst Commentary Recent Street commentary reflects a mix of optimism and recalibration around Autolus Therapeutics, with bullish analysts pointing to early commercial trends for Aucatyzl as a key driver for their views on valuation and execution.Anlatı Güncellemesi • May 03
AUTL: Rebased Profit Assumptions Set Stage For Future Upside Execution
Analysts have reduced their price targets on Autolus Therapeutics by $2 to $3, citing updated assumptions on discount rates, profit margins, and future P/E levels that temper prior expectations. Analyst Commentary Bullish Takeaways Bullish analysts see the updated discount rates and profit margin assumptions as a reset that can make future execution milestones more impactful for valuation, rather than relying on aggressive prior models.Anlatı Güncellemesi • Apr 18
AUTL: Higher Risk Assumptions Will Still Support Upside Potential
Analysts have modestly lifted their fair value estimate for Autolus Therapeutics from $8.79 to $8.81, tying the change to updated assumptions for discount rates, revenue growth, profit margins, and future P/E, along with recent price target revisions from the Street. Analyst Commentary Recent Street research has focused on recalibrating price targets for Autolus Therapeutics, which feeds directly into the modest change in fair value.Anlatı Güncellemesi • Mar 31
AUTL: Lower 2026 Sales Guidance Will Still Support Upside Potential
Analysts have trimmed their price targets on Autolus Therapeutics by $2 to $3 following updated 2026 Aucatzyl sales guidance of $120M to $135M, as well as a recalibration of revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research notes highlight a mixed but focused view on Autolus Therapeutics, centered on execution against updated Aucatzyl sales guidance, cost structure, and how these flow through to valuation assumptions.Seeking Alpha • Mar 27
Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts
Summary Autolus Therapeutics plc maintains a Hold rating due to a challenging risk/reward profile despite strong clinical data for Aucatzyl in r/r B-ALL. 2026 guidance targets $120–$135m in product revenues and a shift to positive gross margin, with AUTL's cash runway projected into Q4 2027. Key catalysts include pediatric ALL Phase 2 data (2027) and initial MS autoimmune data (late 2026), both with significant upside potential. Competitive pressures, funding needs beyond 2027, and uncertain commercial uptake in cell therapy remain material risks for AUTL. Read the full article on Seeking AlphaAnaliz Makalesi • Feb 03
The Market Doesn't Like What It Sees From Autolus Therapeutics plc's (NASDAQ:AUTL) Revenues Yet As Shares Tumble 26%
Autolus Therapeutics plc ( NASDAQ:AUTL ) shareholders won't be pleased to see that the share price has had a very rough...Analiz Makalesi • Dec 20
Autolus Therapeutics plc's (NASDAQ:AUTL) Shares Bounce 28% But Its Business Still Trails The Industry
Autolus Therapeutics plc ( NASDAQ:AUTL ) shares have had a really impressive month, gaining 28% after a shaky period...Yeni Anlatı • Aug 17
Robust Clinical Uptake Will Expand Advanced Cancer Therapy Adoption
Key Takeaways Accelerating adoption, regulatory progress, and expanded clinical indications position Autolus for increased market share and long-term revenue growth in advanced cancer therapies. Improved manufacturing efficiency and financial discipline strengthen margins, enabling investment in innovation and geographic expansion while supporting sustained profitability.Analiz Makalesi • Apr 04
Industry Analysts Just Upgraded Their Autolus Therapeutics plc (NASDAQ:AUTL) Revenue Forecasts By 12%
Celebrations may be in order for Autolus Therapeutics plc ( NASDAQ:AUTL ) shareholders, with the analysts delivering a...Seeking Alpha • Mar 04
Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy
Summary Autolus Therapeutics' main focus is on obe-cel, a CAR T-cell therapy for B-cell ALL, with a strong likelihood of approval. AUTL has $657.1 million in cash, providing a cash runway of approximately 3 years, alleviating immediate financial concerns. The company faces significant competition in the CD19 CAR T-cell therapy market, making sales execution crucial for success. Despite the competitive landscape, AUTL's broad pipeline and recent approval of obe-cel position it well for future growth. Read the full article on Seeking AlphaSeeking Alpha • Feb 05
Autolus Therapeutics Will Remain Depressed For A While
Summary Autolus Therapeutics' obe-cel, branded Aucatzyl, is the first CAR-T therapy approved without a REMS, highlighting its safety and unique mechanism. Despite initial stock surge post-approval, AUTL's stock has steadily declined due to market skepticism on CAR-T's financial efficiency and pre-approval fundraising. AUTL's financials show a strong cash position but poor market performance, with the stock trading below cash value, excluding debt. The market demands sustained earnings and cautious fund-raising, suggesting AUTL's stock will remain depressed for the next 3-4 years. Read the full article on Seeking AlphaAnaliz Makalesi • Jan 07
Is Autolus Therapeutics (NASDAQ:AUTL) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Nov 21
AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market
Summary Autolus Therapeutics' AUCATZYL, approved by the FDA for relapsed/refractory B-cell ALL, shows strong potential despite safety concerns. The Company’s Obe-cel family and oncology pipeline include multiple catalysts for 2025, expanding potential indications in autoimmune diseases and hematologic malignancies. AUTL's cash runway of 1.9 years and no financial debt provide a solid financial foundation to support AUCATZYL's commercialization and future growth. Key risks include scaling manufacturing, securing insurance coverage, and expanding treatment centers, but these are manageable, supporting a bullish long-term outlook. Autolus's valuation appears undervalued given AUCATZYL's market potential and robust pipeline, including multiple CAR T-cell therapies in various trial stages. Read the full article on Seeking AlphaSeeking Alpha • Sep 06
Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case
Summary Autolus Therapeutics plc has a PDUFA date upcoming for its cell therapy obe-cel, indicated for B-ALL. The FDA will decide whether to approve the drug for commercial use. There is already a cell therapy approved in this indication, as well as Amgen's blincyto, but obe-cel's safety and efficacy profile appears strong. Autolus has taken its time gathering the data required to push for approval, but now it has US and EU approval in its sights. An intriguing secondary catalyst is obe-cel in autoimmune disease systemic lupus erythematosus - positive data could send the share price soaring. I have followed Autolus for some time, and my “buy” calls have not come off — but I remain optimistic there is a cell therapy player of note here and I am keeping the faith. Read the full article on Seeking AlphaAnaliz Makalesi • Aug 15
Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Jul 31
Autolus Therapeutics: Major Inflection Point On The Horizon
Summary Today, we are putting T cell developmental firm Autolus Therapeutics plc back in the spotlight for the first time in a year and a half. The company could garner its first FDA approval later this year, and recently signed an enhanced partnership arrangement with a large player in the biotech space. An updated analysis around Autolus Therapeutics follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • May 14
Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity
Summary Autolus Therapeutics now has years of operational runway after recent financing. Operating expenses are manageable, with numerous pipeline projects in the hopper. Autolus likely has an approved therapy on their hands, just waiting for the November action date to realize it. Read the full article on Seeking AlphaAnaliz Makalesi • Nov 06
We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Analiz Makalesi • Jun 26
Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Hissedar Getirileri
| AUTL | US Biotechs | US Pazar | |
|---|---|---|---|
| 7D | 4.3% | 1.2% | 1.0% |
| 1Y | 10.4% | 34.9% | 28.7% |
Getiri vs. Endüstri: AUTL geçen yıl % 34.9 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.
Getiri vs Piyasa: AUTL geçen yıl % 28.7 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| AUTL volatility | |
|---|---|
| AUTL Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: AUTL son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: AUTL 'nin haftalık oynaklığı ( 10% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2014 | 753 | Chris Itin | www.autolus.com |
Klinik aşamada bir biyofarmasötik şirketi olan Autolus Therapeutics plc, Birleşik Krallık'ta ve uluslararası alanda kanser ve otoimmün hastalıkların tedavisi için T hücre tedavileri geliştirmektedir. Şirket, yeni bir anti-CD19 kimerik antijen reseptörünü ifade etmek için bir lentiviral vektör ile transdüklenen otolog T hücrelerinden oluşan bir gen terapisi ürünü olan AUCATZYL'yi sunmaktadır. Ayrıca sistemik lupus eritematozus, progresif multipl skleroz, B-NHL ve KLL ve CNS lenfomasını tedavi etmek için faz 1'de olan obe-cel'i; pediatrik B-ALL ve lupus nefritini tedavi etmek için faz 2'de olan obe-cel'i; pediatrik B-ALL'yi tedavi etmek için faz 1'de olan AUTO1/22'yi geliştirmektedir; Çoklu miyelom ve hafif zincir amiloidozunu tedavi etmek için faz 1 aşamasında olan AUTO8; periferik TCL'yi tedavi etmek için klinik öncesi aşamada olan AUTO4/5; nöroblastomu tedavi etmek için faz 1 aşamasında olan AUTO6NG; ve akut miyeloid lösemiyi tedavi etmek için klinik öncesi aşamada olan AUTO9.
Autolus Therapeutics plc Temel Bilgiler Özeti
| AUTL temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$439.14m |
| Kazançlar(TTM) | -US$288.96m |
| Gelir(TTM) | US$92.62m |
4.9x
P/S Oranı-1.6x
F/K OranıAUTL aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| AUTL gelir tablosu (TTM) | |
|---|---|
| Gelir | US$92.62m |
| Gelir Maliyeti | US$208.48m |
| Brüt Kâr | -US$115.85m |
| Diğer Giderler | US$173.11m |
| Kazançlar | -US$288.96m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -1.09 |
| Brüt Marj | -125.08% |
| Net Kâr Marjı | -311.98% |
| Borç/Özkaynak Oranı | 325.9% |
AUTL uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/22 14:22 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Autolus Therapeutics plc 16 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| James Shin | Deutsche Bank |
| Rajan Sharma | Goldman Sachs |
| Emily Bodnar | H.C. Wainwright & Co. |